newsfilter
← Latest News
ACCESS Newswire·

Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results

~ Fourth Quarter Highlighted by Clinical and Regulatory Milestones Positioning PF614 for Late-Stage Advancement ~SAN DIEGO, CA / ACCESS Newswire / March 30, 2026 / Ensysce Biosciences, Inc. ("Ensysce" or